Integragen (ALINT) - Total Assets
Based on the latest financial reports, Integragen (ALINT) holds total assets worth €3.60 Million EUR (≈ $4.21 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALINT cash generation efficiency for how efficiently the company converts equity into cash flow.
Integragen - Total Assets Trend (2008–2024)
This chart illustrates how Integragen's total assets have evolved over time, based on quarterly financial data. See current stock price of Integragen for real-time trading data and today's change.
Integragen - Asset Composition Analysis
Current Asset Composition (December 2024)
Integragen's total assets of €3.60 Million consist of 95.4% current assets and 4.6% non-current assets. Explore Integragen working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.5% |
| Accounts Receivable | €3.16 Million | 57.2% |
| Inventory | €205.00K | 3.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Integragen's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integragen's current assets represent 95.4% of total assets in 2024, a decrease from 96.7% in 2008.
- Cash Position: Cash and equivalents constituted 34.5% of total assets in 2024, up from 1.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 59.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 57.2% of total assets.
Integragen Competitors by Total Assets
Key competitors of Integragen based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.31 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
Integragen - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.53 | 1.49 |
| Quick Ratio | 1.10 | 1.44 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.81 |
| Working Capital | €549.37K | €2.07 Million | €2.82 Million |
Integragen - Advanced Valuation Insights
This section examines the relationship between Integragen's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.49 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -31.1% |
| Total Assets | €5.51 Million |
| Market Capitalization | $319.78K USD |
Valuation Analysis
Below Book Valuation: The market values Integragen's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Integragen's assets decreased by 31.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Integragen (2008–2024)
The table below shows the annual total assets of Integragen from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €5.51 Million ≈ $6.45 Million |
-31.07% |
| 2023-12-31 | €8.00 Million ≈ $9.35 Million |
-11.33% |
| 2022-12-31 | €9.02 Million ≈ $10.55 Million |
-6.05% |
| 2021-12-31 | €9.60 Million ≈ $11.23 Million |
+8.87% |
| 2020-12-31 | €8.82 Million ≈ $10.31 Million |
+30.74% |
| 2019-12-31 | €6.75 Million ≈ $7.89 Million |
-21.38% |
| 2018-12-31 | €8.58 Million ≈ $10.03 Million |
-0.77% |
| 2017-12-31 | €8.65 Million ≈ $10.11 Million |
+13.96% |
| 2016-12-31 | €7.59 Million ≈ $8.87 Million |
-11.95% |
| 2015-12-31 | €8.62 Million ≈ $10.08 Million |
-6.00% |
| 2014-12-31 | €9.17 Million ≈ $10.72 Million |
+58.55% |
| 2013-12-31 | €5.78 Million ≈ $6.76 Million |
-26.36% |
| 2012-12-31 | €7.85 Million ≈ $9.18 Million |
+12.73% |
| 2011-12-31 | €6.97 Million ≈ $8.15 Million |
-14.82% |
| 2010-12-31 | €8.18 Million ≈ $9.56 Million |
+95.36% |
| 2009-12-31 | €4.19 Million ≈ $4.90 Million |
+17.07% |
| 2008-12-31 | €3.58 Million ≈ $4.18 Million |
-- |
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more